Videos / Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler
In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).
This educational activity was developed by Healthed at the request of and with funding from GSK.
PM-AU-FVU-OGM-220003 approved June 2022
Heart Failure – Demystifying Pharmacological Management for GPs
Iron Deficiency in Children & Young People
Heart Failure – Assessment and Monitoring in Primary Care
COPD Update